Floatz logo

FILGRASTIM

Multiple Myeloma and Plasma Cell Neoplasm

Jonsson Comprehensive Cancer Centerprotein_peptidePhase 4 / ApprovedDormant
BBB
79/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
73/ 100
Competitive Position
89/ 100

Competitive context

498 Active assets in the Multiple Myeloma and Plasma Cell Neoplasm cohort.

Asset / SponsorPhaseRating
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Inno-206
University of Arkansas
Phase 3BBB
Busulphan
M.D. Anderson Cancer Center
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB
CYCLOSPORIN A
Seoul National University Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

FILGRASTIM is also rated in:

Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Myelodysplastic/Myeloproliferative NeoplasmsDormant
BBB
Indicative ·
76 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →